Zinc supplementation ameliorates type 2 diabetes markers through the enhancement of total antioxidant capacity in overweight patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This study aimed to evaluate the effects of zinc supplementation on the oxidative status in overweight T2DM.

In addition, the routine glycaemic parameters were determined and compared in zinc-treated and placebo groups.

Who Took Part

The study group was 70 patients.

In this randomised, double-blind, placebo-controlled trial, 70 patients with T2DM were selected.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Blood samples were collected from all the individuals in the zinc group and controls for analysis.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Antioxidants, Overweight, Zinc, Blood Glucose, Insulin and Dietary Supplements.

Author keywords: Biochemistry, Clinical trials, Diabetes & endocrinology, General diabetes and Nutritional support.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 70 patients.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Postgraduate medical journal), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.